The latest price target for Alzamend Neuro (NASDAQ:ALZN) was reported by Maxim Group on April 12, 2023. The analyst firm set a price target for $1.50 expecting ALZN to rise to within 12 months (a possible 260.75% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Alzamend Neuro (NASDAQ:ALZN) was provided by Maxim Group, and Alzamend Neuro initiated their buy rating.

There is no last upgrade for Alzamend Neuro

There is no last downgrade for Alzamend Neuro.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alzamend Neuro, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alzamend Neuro was filed on April 12, 2023 so you should expect the next rating to be made available sometime around April 12, 2024.

While ratings are subjective and will change, the latest Alzamend Neuro (ALZN) rating was a initiated with a price target of $0.00 to $1.50. The current price Alzamend Neuro (ALZN) is trading at is $0.42, which is within the analyst’s predicted range.